NCT00097591

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 13,619 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.

Conditions

• Coronary Arteriosclerosis
• Acute Coronary Syndromes

Interventions

Type	Name	Description
DRUG	Prasugrel	Administered orally
DRUG	Clopidogrel	Administered orally

Timeline

• Start date: 2004-11-01
• Primary completion: 2007-07-01
• Completion: 2007-07-01
• First posted: 2004-11-25
• Last updated: 2010-09-16
• Results posted: 2010-09-16

Locations

1 site across 1 country: United States